（股份代號：06160） BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 員工購股計劃項下的股份購買 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。茲提述本公司日期 為2025年3月6日的公告（「該公告」），內容有關董事會於2025年5月27日批准的第 五份經修訂及經重列2018員工購股計劃（「2018員工購股計劃」）項下的認購期自 2025年3月3日至2025年8月29日期間的股份購買。除另有界定者外，本公告所用 詞彙與該公告所定義者具有相同涵義。 關於2018員工購股計劃項下的股份購買的更新 如該公告所披露，2018員工購股計劃使合資格僱員可按市價15%折讓申購股份 （包括以美國存託股份的形式）。僱員可於認購期結束後購買股份，購股資金可從 其認購期內所得薪金中扣除。 公司謹此向其股東告知並宣佈，截至2025年3月3日至2025年8月 ...

Core Viewpoint - BeiGene (06160.HK) announced that a total of 62,962 American Depositary Shares (ADS) were purchased by 3,932 participants under the 2018 Employee Stock Purchase Plan during the subscription period from March 3, 2025, to August 29, 2025, representing approximately 0.05% of the company's total issued shares as of the announcement date [1]. Summary by Category - **Company Actions** - The company reported the purchase of 62,962 ADS by employees, indicating active participation in the employee stock purchase plan [1]. - The total number of shares involved in the purchase is 818,506 [1]. - **Financial Impact** - The purchased ADS represents about 0.05% of the total issued shares of the company as of the announcement date [1].

Core Viewpoint - The announcement from BeiGene indicates that a total of 3,932 participants purchased 62,962 American Depositary Shares (ADS) under the 2018 Employee Stock Purchase Plan, representing approximately 0.05% of the company's total issued shares [1] Summary by Relevant Sections - **Employee Participation**: A total of 3,932 participants engaged in the stock purchase plan [1] - **Shares Purchased**: Participants acquired 62,962 ADS, which corresponds to 81.85 million shares [1] - **Share Price**: The price per ADS was set at $208.7, equating to approximately HKD 125.06 per ordinary share [1] - **Total Amount Deducted**: The authorized salary deduction amount during the subscription period was $13.4495 million [1]

Core Viewpoint - The Hong Kong innovative drug sector has rebounded significantly after a previous decline, with major companies experiencing substantial stock price increases, indicating a positive market sentiment despite concerns over potential restrictions from the U.S. on Chinese innovative drugs [1][2][3]. Group 1: Market Performance - The Hong Kong innovative drug index (HK1105) fell approximately 3.82% due to market rumors but has since rebounded, with notable stocks like Innovent Biologics (09969.HK) rising over 12% to nearly historical highs [2][3]. - The A-share innovative drug index (BK1106) also saw a rise of 1.08%, with several companies achieving significant stock price increases, including Innovent Biologics-U (688428.SH) which rose over 12% [2][3]. - Since April 9, the A-share and Hong Kong innovative drug sectors have shown strong performance, with the A-share index increasing by 62% and the Hong Kong index by over 130% [3]. Group 2: Company Developments - Companies like Innovent Biologics and BeiGene are expected to reach profitability by 2025, with many biotech firms anticipated to enter a profitable cycle due to improved industrial capabilities and product line expansions [1][3]. - Recent approvals, such as Innovent Biologics' drug for treating relapsed/refractory marginal zone lymphoma, have acted as key catalysts for stock price increases [5]. - A total of 17 innovative drug companies are projected to reach new stock price highs by 2025, with significant gains observed in both A-share and Hong Kong markets [3]. Group 3: Financial Performance - The innovative drug sector is expected to see a total revenue of 449 billion yuan in the first half of 2025, reflecting a year-on-year growth of 31.48%, with 62% of companies reporting positive revenue growth [6][9]. - Notably, companies like BeiGene and Innovent Biologics have reported over 40% year-on-year revenue growth, marking a significant turnaround in profitability for many firms [11][12]. - The overseas licensing agreements for Chinese innovative drugs have reached a total of 943 billion USD, significantly surpassing the previous year's total, indicating strong international market potential [12][14]. Group 4: Policy and Regulatory Environment - Recent regulatory changes have favored the innovative drug sector, with policies aimed at optimizing clinical trial approvals and reducing supply chain risks, which are expected to benefit innovative drug companies [6][14]. - The introduction of mechanisms to support non-winning bidders in drug procurement is anticipated to enhance the market environment for innovative drugs, moving away from a solely price-based evaluation [14].

Core Insights - BeiGene (06160.HK) announced that a total of 62,962 American Depositary Shares (ADS) were purchased by 3,932 participants under the 2018 Employee Stock Purchase Plan during the subscription period from March 3, 2025, to August 29, 2025 [1] - The number of ADS purchased amounts to 818,506, representing approximately 0.05% of the total issued shares of the company as of the date of the announcement [1]

BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 （股份代號：06160） 員工購股計劃項下的股份購買 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。茲提述本公司日期 為2025年3月6日的公告（「該公告」），內容有關董事會於2025年5月27日批准的第 五份經修訂及經重列2018員工購股計劃（「2018員工購股計劃」）項下的認購期自 2025年3月3日至2025年8月29日期間的股份購買。除另有界定者外，本公告所用 詞彙與該公告所定義者具有相同涵義。 關於2018員工購股計劃項下的股份購買的更新 如該公告所披露，2018員工購股計劃使合資格僱員可按市價15%折讓申購股份 （包括以美國存託股份的形式）。僱員可於認購期結束後購買股份，購股資金可從 其認購期內所得薪金中扣除。 公司謹此向其股東告知並宣佈，截至2025年3月3日至2025年8月 ...

智通财经APP讯，百济神州(06160)发布公告，于2025年9月11日因根据第五版经修订及重列的2018员工 购股权计划而发行普通股81.85万股。 ...

百济神州(06160)发布公告，于2025年9月11日因根据第五版经修订及重列的2018员工购股权计划而发行 普通股81.85万股。 ...

百济神州(6160.HK)今日盘中一度涨5.26%至204港元，年内累涨约87%。消息面上，联交所权益披露资料显示，百济神州于9月9日获The Capital Group Companies, Inc.在场内以每股均价348.12港元增持88.26万股，涉资约3.07亿港元。增持后，其持股比例由4.96%上升至5.02%。(格隆汇) | 股份代號: | 06160 | | --- | --- | | 上市法國名稱: | 百濟神州有限公司 | | 日期 (日 / 月 / 年): | 12/08/2025 - 12/ | | 表格序號 | | 大股東/董事/最高行政人員名 | | | 作出披露的 買入 / 賣出或涉及的 | | 每股的平均價 | 持有權益的股份數目 | | 佔已發行的 有關事件的日期相 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 景区 | | 股份數目 | | | (請參閱上述*註 | | 有投票權股 (日 / 月 / 年) | | | | | | | | | | | | 份百分比 % ...

Core Viewpoint - The article discusses the significant fluctuations in stock prices of innovative pharmaceutical companies, highlighting both the successes and failures in the market, particularly focusing on the performance of companies that reached historical highs in 2025 and those that have experienced substantial declines. Group 1: Performance of Innovative Pharmaceutical Companies - As of September 11, 2025, 90% of Hong Kong and STAR Market innovative pharmaceutical companies have seen significant stock price increases since the beginning of the year [6] - A total of 17 companies reached historical highs in stock price and market capitalization in 2025, with notable companies including BeiGene (688235.SH) and Innovent Biologics (01801.HK) [7][10] - Among these 17 companies, 12 have entered or are about to enter the commercialization phase, establishing stable revenue sources [7] Group 2: Key Events and Financial Performance - BeiGene and Innovent Biologics achieved their first profits in the first half of 2025, with BeiGene reporting a net profit of approximately 450 million yuan, a significant turnaround from a loss of 2.877 billion yuan in the same period last year [10] - Innovent Biologics reported a net profit of 834 million yuan, benefiting from the growth of PD-1 and other oncology drugs in the domestic market [10] - Other companies like Kintor Pharmaceutical (06990.HK) and Rongchang Biologics (688331.SH) have also made significant progress through BD transactions and drug approvals [11] Group 3: Declining Companies and Market Challenges - Despite the successes, 50% of innovative pharmaceutical companies still have stock prices below their initial offering prices, with 31 out of 55 Hong Kong 18A innovative pharmaceutical stocks experiencing declines [14][15] - Companies like Tengsheng Bo Pharmaceutical (02137.HK) and Akeso (09939.HK) have seen significant drops in stock prices, with some losing over 90% of their value since their IPOs [20][21] - The article notes that many of these declining companies faced challenges such as failed drug trials or adverse market conditions, leading to substantial losses [20][21] Group 4: Recent Trends and Future Outlook - Three companies, including Tongyuan Kang Pharmaceutical (02410.HK), have seen stock price declines of 70% or more since the beginning of the year, indicating ongoing volatility in the sector [25] - The article emphasizes the importance of BD transactions and successful drug approvals as key factors for recovery and growth in the innovative pharmaceutical market [12][22]